PubMed Health⌕ Search

Biomedical subjects

H E Lehmann

Publications and source records attributed to H E Lehmann.

At least 19 recordsLinked to original sources
PubMed1979

Negative aspects of psychotherapeutic drug treatment.

Negative effects of psychotropic substances may be divided into seven categories: 1. Physical symptoms, e.g. headache, dry mouth, etc. 2. Somatic complications, i.e. conditions which seriously impair the patient's health, e.g. choleostatic jaundice or tardive dyskinesia. 3. Behavioural toxicity, i.e. noxious modifications of the patient's behaviour as the result of the drug's action, e.g. drug-dependence, psycho-motor retardation, etc. 4. Compliance problems, i.e. irregular or unreliable adherence to the prescribed drug regime by the patient. 5. Restriction of the patient's learning capacity, which may represent an obstacle to the application of other treatment modalities, e.g. behaviour modification, or to the patient's social re-adaptation. 6. Psychodynamic interference with psychotherapy, e.g. by diminishing the patient's motivation to pursue this type of treatment or by disturbing the structure of his defences. 7. Reducing the physicians' therapeutic efficacy if he relies exclusively on psychotropic agents.

Behavior↗
PubMed1979

Problems with ethical aspects of psychotropic drug use.

1. Research is an important area within the purview of medical ethics. The Nuremberg Code and the Helsinki Declaration provide well established guidelines in this field. 2. Specific ethical issues still requiring clarification in psychopharmacological research are the informed consent, the benefit/risk ratio and the choice of placebo or standard. 3. Peer review committees, if well chosen for their objectivity, general competence and special expertise, are likely to be the best arbiters regarding such questions. 4. Legislation and other political interventions--unfortunately not always objective, competent or expert in the exercise of their powers--have recently developed into rampant paraethical problems that are plaguing medical treatment and research in many parts of the world and need to be dealt with urgently through internationally coordinated efforts. The WHO would appear to be the most appropriate agency for such action.

Ethics Committees, Clinical↗
PubMed1978

A review of nicotinic acid, N-methylated indoleamines and schizophrenia.

The hypothesis that endogenously formed, N-methylated metabolites of indoleamines may play a role in the pathogenesis of schizophrenia was reviewed. Although N-methylated indoleamines can be produced in vivo and have significant psychotomimetic effects, there is little evidence for a specific increase in the methylation of indoleamines in schizophrenic patients. It was noted that even if the relationship between schizophrenia and N-methylated indoleamines had existed, nicotinic acid would not be an appropriate therapeutic agent.

Bufotenin↗
PubMed1978

Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial.

A 16-week, standard-controlled, double-blind study was conducted to compare the efficacy of butaclamol with that of fluphenazine in the treatment of 24 newly admitted schizophrenic patients. Statistically significant improvement occurred in the entire population in the total scores of the BPRS and PAS; in the activation, anergia, thought disturbance and hostile/suspiciousness factor scores of the BPRS; and in the scores of 9 of the 12 factors of the PAS. There were no statistically significant differences between the scores of the two treatment groups on the total or factor scores of either scale during the course of the clinical trial. The most frequently occurring adverse effects in the butaclamol group were rigidity, akathisia and excitement/agitation. The most frequently occurring adverse effects in the fluphenazine group were insomnia, decreased motor activity and tremor. It is concluded that butaclamol exerts potent neuroleptic effects on schizophrenic patients.

Adult↗
PubMed1977

WIN 27,147-2 in the treatment of depression. An uncontrolled clinical study.

An uncontrolled clinical study with WIN 27,147-2 was conducted with 10 hospitalized depressed psychiatric patients. There was statistically significant improvement in the total scores of the HAM-D, BPRS and Zung; in the scores of all the factors of the HAM-D and Zung; in the scores of the anxiety/depression and activation factors of the BPRS, and in the scores of 6 of the 18 items of the BPRS. Judged by clinical global impression, 9 of the 10 patients were very much improved and 1 patient much improved. The most frequently occurring adverse effects were dry mouth, sweating, drowsiness and insomnia.

Adult↗
PubMed1977

Transmethylation hypothesis of schizophrenia: methionine and nicotinic acid.

The transmethylation hypothesis of schizophrenia was reviewed with considerations that large doses of methionine when combined with a monoamine oxidase inhibitor lead to exacerbation of psychotic symptoms in a significant percentage of chronic schizophrenic patients. It was noted that nicotinic acid in the dosage of 3,000 mg/day can neither prevent nor counteract the psychopathology thus induced.

Catechol O-Methyltransferase↗